VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Recent updates from the PROMISE study

Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, shares some updates from the PROMISE study (NCT03689595), which is screening high-risk individuals for precursor conditions including monoclonal gammopathy of undetermined significance (MGUS) and monoclonal gammopathy of indeterminate potential (MGIP). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter